Bioequivalence and Pharmacokinetic Evaluation of Two Oral Formulations of Regorafenib: An Open-Label, Randomised, Single-Dose, Two-Period, Two-Way Crossover Clinical Trial in Healthy Chinese Volunteers Under Fasting and Fed Conditions

BACKGROUND: Regorafenib is an oral multi-kinase inhibitor approved for the treatment of solid tumours, but the pharmacokinetic profile of regorafenib in the Chinese population is unclear. OBJECTIVE: The aim of this study was to examine the pharmacokinetics, bioequivalence, and safety of two formulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qian, Wang, Zhiqiang, Wu, Jingying, Zhou, Zhen, Zhou, Renpeng, Hu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328391/
https://www.ncbi.nlm.nih.gov/pubmed/34349503
http://dx.doi.org/10.2147/DDDT.S323169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328391/
https://www.ncbi.nlm.nih.gov/pubmed/34349503
http://dx.doi.org/10.2147/DDDT.S323169

Ejemplares similares